Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Moonlake Immunotherapeutics (MLTX)
:MLTX
RESEARCH TOOLSreports
Holding MLTX?
Track your performance easily
MLTX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$37.55 - $64.98
Previous CloseN/A
Volume45.38K
Average Volume (3M)294.17K
Market Cap
$2.65B
Enterprise Value$2.69B
Total Cash (Recent Filing)$1.34M
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.61
Next Earnings
Mar 24, 2025EPS Estimate
-0.62Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.29
Shares Outstanding63,063,930
10 Day Avg. Volume493,842
30 Day Avg. Volume294,166
Standard Deviation0.20
R-Squared0.09
Alpha0.03
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-27.80
P/FCF Ratio0.00
Enterprise Value/Market Cap1.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-36.07
Forecast
1Y Price Target
$79.20Price Target Upside90.98% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
MoonLake Immunotherapeutics News
PremiumCompany Announcements
MoonLake Immunotherapeutics Announces Board Changes and Incentives
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe initiation of new studies is seen as positive progress in expanding the market opportunity for SLK.
Competitive AdvantageSLK’s 24-week data in PsA showed numerically better results than that of bimekizumab, suggesting a competitive advantage in treatment efficacy.
Market PotentialNew clinical studies should, if positive, significantly expand market potential for SLK beyond forecasts.
Bears Say
Clinical TrialsInability to advance SLK in pivotal trials in a timely fashion and failure of SLK to show compelling clinical efficacy in pivotal trials.
Financial PerformanceHigher-than-anticipated R&D spending resulted in a relatively modest difference in net loss.
Regulatory ChallengesDelays in completing regulatory submissions for SLK in key territories.
---
Ownership Overview
25.92% Insiders
15.86% Mutual Funds
0.13% Other Institutional Investors
57.53% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MLTX FAQ
What was Moonlake Immunotherapeutics’s price range in the past 12 months?
Moonlake Immunotherapeutics lowest stock price was $37.55 and its highest was $64.98 in the past 12 months.
What is Moonlake Immunotherapeutics’s market cap?
Moonlake Immunotherapeutics’s market cap is $2.65B.
When is Moonlake Immunotherapeutics’s upcoming earnings report date?
Moonlake Immunotherapeutics’s upcoming earnings report date is Mar 24, 2025 which is in 65 days.
How were Moonlake Immunotherapeutics’s earnings last quarter?
Moonlake Immunotherapeutics released its earnings results on Nov 07, 2024. The company reported -$0.56 earnings per share for the quarter, missing the consensus estimate of -$0.435 by -$0.125.
Is Moonlake Immunotherapeutics overvalued?
According to Wall Street analysts Moonlake Immunotherapeutics’s price is currently Undervalued.
Does Moonlake Immunotherapeutics pay dividends?
Moonlake Immunotherapeutics does not currently pay dividends.
What is Moonlake Immunotherapeutics’s EPS estimate?
Moonlake Immunotherapeutics’s EPS estimate is -0.62.
How many shares outstanding does Moonlake Immunotherapeutics have?
Moonlake Immunotherapeutics has 63,063,930 shares outstanding.
What happened to Moonlake Immunotherapeutics’s price movement after its last earnings report?
Moonlake Immunotherapeutics reported an EPS of -$0.56 in its last earnings report, missing expectations of -$0.435. Following the earnings report the stock price went down -1.573%.
Which hedge fund is a major shareholder of Moonlake Immunotherapeutics?
Among the largest hedge funds holding Moonlake Immunotherapeutics’s share is Woodline Partners LP. It holds Moonlake Immunotherapeutics’s shares valued at 12M.
---
MoonLake Immunotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$79.20 (90.98% Upside)
$79.20 (90.98% Upside)
Blogger Sentiment
Neutral
MLTX Sentiment 50%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 5.7K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 0.3%
Last 30 Days ▲ 2.6%
Last 30 Days ▲ 2.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-28.07%
12-Months-Change
Fundamentals
Return on Equity
-17.69%
Trailing 12-Months
Asset Growth
3.60%
Trailing 12-Months
Company Description
Moonlake Immunotherapeutics
Helix Acquisition Corp is a blank check company.
---
MLTX Stock 12 Month Forecast
Average Price Target
$79.20
▲(90.98% Upside)
Technical Analysis
TScan Therapeutics
―
Revolution Medicines
―
Instil Bio
―
Aurinia Pharmaceuticals
―
Immunocore Holdings
―
Sana Biotechnology
―
Best Analysts Covering MLTX
1 Year
1 Year Success Rate
12/19 ratings generated profit
1 Year Average Return
+104.53%
reiterated a buy rating 2 months ago
Copying Thomas Smith's trades and holding each position for 1 Year would result in 63.16% of your transactions generating a profit, with an average return of +104.53% per trade.
---